Last updated on July 2018

A Study to Assess the Safety Tolerability Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients


Brief description of study

This is a double-blind placebo controlled, randomized, phase 2 study to assess the safety, tolerability, pharmacokinetics and efficacy of twice daily topical applications of AP611074 5% Gel for up to 16 weeks in condyloma patients

Clinical Study Identifier: NCT02724254

Contact Investigators or Research Sites near you

Start Over

Eric Wenzel

Anaconda Invesigational Site
Buenos Aires, Argentina

Eric Wenzel

Anaconda Investigational Site
Buenos Aires, Argentina

Eric Wenzel

Anaconda Investigational Site
Cordoba, Argentina

Eric Wenzel

Anaconda Investigational Site
Mendoza, Argentina

Eric Wenzel

Anaconda Investigational Site
Sante Fe, Argentina

Eric Wenzel

Anaconda Investigational Site
Santiago, Chile

Eric Wenzel

Anaconda Investigational Site
Cumbaya, Ecuador

Eric Wenzel

Anaconda Investigational Site
Guayaquil, Ecuador

Eric Wenzel

Anaconda Investigational Site
Quito, Ecuador

Eric Wenzel

Anaconda Investigational Site
Belgrade, Serbia

Eric Wenzel

Anaconda Investigational Site
Novi Sad, Serbia

Eric Wenzel

Anaconda Investigational Site
Córdoba, Argentina

Eric Wenzel

Anaconda Investigational Site
Concepción, Chile